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Introduction
Every year more than 250,000 people develop pancre-
atic cancer. Because no effective treatment for the dis-
ease has been found, the mortality rate is practically
100% [1].
The spread of the neoplasm in the abdominal cavi-
ty leads to the development of ascites, which is a com-
plex process. Both the increased permeability of the
microcirculation system of the tumour and its very
presence intensify the production of ascitic fluid. The
aggressiveness of the neoplasm and the development
of metastasis largely depend on the vascular endothe-
lial growth factor (VEGF) and the vascular permeabil-
ity factor (VPF) [2-4].
The characteristic conditions under which ascitic
fluid caused by neoplastic changes is produced have
led to the development of a method for intraperitoneal
administration of antineoplastic drugs [5].
Almost entire doses of conventional synthetic cyto-
statics are absorbed from the peritoneum by blood and
so doses used in intraperitoneal treatment are identical
to those administered intravenously. In some cases
ascitic fluid may prove helpful in designing new meth-
ods of treatment for this cancer consisting in intraperi-
toneal administration of cytostatics [2]. Intraperitoneal
chemotherapy uses cytostatics that have a small
molecular weight and so penetrate through the mem-
brane separating ascitic fluid from the patient's blood,
making their way into the blood and causing the same
side effects as in the case of intravenous chemothera-
py. Intraperitoneal treatment is used for neoplasms of
the ovary, pancreas or liver [6,7].
Toxic cytostatics administered intraperitoneally
even in doses many times exceeding standard intra-
venous doses have been shown experimentally not to
irritate the peritoneum or cause systemic toxicity.
However, they do not seem to have satisfactory treat-
ment effectiveness. For some time now synthetic tis-
sue metaloproteinase inhibitors (TIMPs) have been
utilised in intravenous and intraperitoneal treatment;
these are used by tumour cells to destroy and remodel
tissue stroma as part of metastasis, but they also block
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angiogenesis, stopping local infiltration, and enable
tumor encapsulation [8,9].
An important role in neoplastic processes is also
played by proteolytic enzymes. Their activity has been
found to increase with the expression of the neoplasm,
its metastasis, angiogenesis and when controlling
apoptosis of neoplastic cells [10].
Overexpression of proteolytic enzymes belonging
to cysteine peptidases (cathepsins B, L or K) is mainly
to be found within the border zone between neoplastic
and healthy tissue, as well as in systemic fluids accom-
panying such changes. Their high activity has been
observed in ascitic fluid caused by the development of
the neoplasm.
Their activity is controlled in vivo by autogenous
inhibitors produced by the body. Overexpression of
such enzymes has been found at places where neoplas-
tic changes occur, but the amount of own inhibitors is
insufficient to stop carcinogenesis [11].
Another approach to developing new treatments is
represented by inhibitors of cysteine peptidases, which
are used to arrest the activity of neoplastic cathepsins B,
K and L. These are able to block the activity of enzymes
determining the activation of apoptosis of cancerous
cells and to control invasion, metastasis and angiogene-
sis. The fact that cysteine peptidases forming inactive
complexes are present in the body attests to the existence
in the body of defensive factors, including autogenous
inhibitors (cystatins or kininogens), but their activity is
hindered by overexpression of cysteine peptidases or
other substances accompanying the neoplastic process.
This suggests that an excess of cysteine peptidases relat-
ed to the neoplastic process may be limited by introduc-
tion into the body of cysteine inhibitors, as this strength-
ens the autogenic immune system [12].
Changes in the activity of peptidases have also
been observed in neoplastic change processes that
accompany the development of pancreatic cancer [13].
The lack of an effective treatment means that
research into new pancreatic cancer therapies should
be intensified. The study focused on the use of cys-
tatins isolated from chicken egg white to inhibit the
activity in ascitic fluid of cysteine peptidases, the
enzymes that induce the key neoplastic processes. The
delivery of inhibitors through ascitic fluid should limit
their potential side effects on the patient. Furthermore,
because of the size of its molecule, the inhibitor should
not be able to permeate the membrane that keeps
ascitic fluid separate from other body fluids and act
within the ascitic water-neoplasm area.
Materials and methods
Biological material. The ascitic fluid needed for the study was
collected from patients with ascites treated for pancreatic cancer.
Fluid samples were taken from 31 patients with diagnosed pancre-
atic cancer. The samples had a volume of 5.0 ml each; they were
first frozen at -20°C, then defrosted and centrifuged at 10,000 rpm.
The obtained deposit was separated, to be used for cytological
examination, and the supernatant was frozen at -20°C. The deposit
was checked cytologically for the presence of cancerous cells. The
supernatants were refrozen at -20°C and kept for further determi-
nations. After defrosting they were first examined for the activity
of cysteine peptidases and then the activity was arrested with a spe-
cific inhibitor – cystatin from chicken egg white. The pure and
sterile inhibitor was dissolved in physiological saline and used in
titration of cystein peptidases in the ascitic fluid supernatant.
Cysteine proteinase inhibitor (CPI, cystatin) was isolated from
eggs as previously described [14].
Measurement of the activity of cysteine peptidases by spectro-
fluorometry. The activity of cysteine peptidases was measured
with a Perkin Elmer UV/VIS Spectrometer Lambda Bio 20 (Perkin
Elmer, Wellesley, MA, USA). One sample contained 100 μl of asc-
ities fluid, diluted with normal saline as needed according to the
concentration of the enzyme; 700 μl 0.4M phosphate buffer at pH
6.0, including 4 mM ethylenediamine tetraacetic acid (EDTA),
2.5mM dithiothreitol (DTT), and 200 μl diluted substrate concen-
trate Z-Phe-Arg-NMec, whose concentration was 40 μM. The sam-
ple was incubated at 37°C for 60 min. The reaction of hydrolysis
was terminated by adding 2.0 ml of 1.0 mM iodoacetic acid to each
sample. Fluorescence of the liberated 7-amino-4-methylcoumarin
(Mec) was measured using the wavelength λ=370 nm for excita-
tion and λ=440nm for emission. The measurements were made in
regard to baseline solution, which differed from the analyzed sam-
ples in that 2.0 ml of iodoacetic acid was added before the sub-
strate. The results are given in units of activity of cysteine
endopeptidases, calculated for the amount of protein appearing in
the sample. One unit of enzyme activity was defined as that
amount of the enzyme that would liberate 1 nM of Mec per 1 min,
calculated for 1mg of protein
Determination of cathepsin B-like activity. Cathepsin B activity
was measured in 100 μl of ascitic fluid supernatant according to
Barretts method. One mEU of activity was defined as the quantity
releasing 1 nM of 7-AMC [15,16].
Inhibition of cathepsin B with egg white cystatin. Initially, vari-
ous amounts of egg white cystatin (25 μg, 50 μg and 100 μg) were
added to 100 μl samples of ascitic fluid in order to determine its
optimum amount. 100 μl samples of ascites fluid supernatant were
added to 500 μl of 0.4 M sodium phosphate activation buffer (pH
6.0) containing 4 mM EDTA, 2.5 mM DTT, and were subsequent-
ly preincubated for 5 min at 37°C before the addition of 100 μl of
a solution containing 100 μg protein of egg white cystatin. The
samples were incubated for 10 minutes at 37°C and than 100 μl of
200 μM Z-Arg-AMC and the incubation was carried out for 30 min
and stopped by the addition of 2 ml of 1 mM iodoacetic acid. Flu-
orescence was measured at 370 nm excitation and 440 nm emis-
sion wavelengths using a Luminescence Spectrometer, Perkin
Elmer LS 50 B. One mEu of inhibitor activity was defined as a
quantity of cathepsin B releasing 1 nM of 7-AMC [14,17].
Statistical analysis. The data were expressed as the mean values
±SD. Walloon's rank test were used. The 0.05 level of probability
was assumed as significant.
Results
Determinations were made for supernatants of ascitic
fluid taken from 31 patients with pancreatic cancer.
First, the activity of cysteine peptidases in the fluid
was determined. Using Z-Arg-AMC as a substrate, total
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activity of cathepsins B, L and K was determined. After-
wards three fluid samples were selected at random in
order to establish the optimum amount of egg white cys-
tatin for inhibiting cysteine peptidase activity so that 10-
30% of the original activity remained. Cystatin was iso-
lated from egg white by means of our own method.
In order to assess the degree of inhibition of
enzyme activity various amounts of egg white cystatin
with an activity of 64.8 mEU/protein were added to the
three samples. The inhibitor was added in the amounts
of 25 μg, 50 μg and 100 μg. The best results were
obtained when 100 μg of the inhibitor were used. The
test results are presented in Table 1. The activity of
cysteine peptidases in all ascitic fluid samples was
most effectively reduced when 100 μg of egg white
cystatin was added. The results are given as percent-
ages of inhibition of the activity of the cysteine pepti-
dases in question. The activity of the enzymes in the
fluids under study was reduced by 70-95%. The results
are presented in Fig. 1 and Fig. 2.
Discussion
The study was aimed at determining the arrest of neo-
plastic processes. It was conducted in two directions.
The first focused on establishing the ability to control
the vascular endothelial growth factor (VEGF) and the
vascular permeability factor (VPF). The protein is
responsible for angiogenesis in neoplastic tissue. It
affects the exchange of the products of metabolism and
a reduction in its concentration may lead to necrosis of
neoplastic tissue. A rise in its concentration facilitates
the growth and nourishment of pathogenic tissue,
which is related to angiogenesis [18]. It seems that a
reduction in VEGF protein or its receptor may be used
as a therapy in neoplastic patients. In tissue unable to
nourish itself and remove the products of metabolism
there develops necrosis, which in this case has a ther-
apeutic effect. The protein, as indicated above, is even
regarded as a prognostic marker associated with neo-
plasms [19].
Changes in the protein concentration have also
been observed in the case of pancreatic cancer; they
can be induced by metaloproteinase inhibitors or the
specific protein antineoplastic drug Bevacizumab. It is
a new generation drug guided on the basis of the anti-
gen/antibody affinity. It is a humanized monoclonal
antibody used for blocking vascular endothelial
growth factor A and is regarded as an angiogenesis
inhibitor [20,21].
The other part of the study concentrated on the role
of proteolytic enzymes and an attempt to control them.
It was found that a number of proteolytic enzymes
control the major stages leading to the development of
neoplasm. The key role in such processes is played by
cysteine peptidases. The enzymes mutually activate
one another and in the end result in the development of
neoplasm. The activity of the enzymes may be con-
trolled with specific inhibitors. Understanding the
processes may lead to the development of new treat-
ments for cancer [22,23].
Big hopes rest on the use of cystatins for control-
ling neoplastic processes such as invasion, metastasis
and angiogenesis. Using the inhibitors it is not only
possible to control enzymatic changes but also VEGF
[24,25].
Of special importance to the arrest of the activity of
cathepsins B, K and L are egg white cystatins. The
inhibitors have been found to control in vitro the activ-
ity of the enzymes in cancerous tissue homogenates in
patients operated for malignant neoplasms of the
digestive track [26].
It has even been discovered that by using immuno-
histochemical tests it is possible to determine egg cys-
tatin-cathepsin B levels in neoplastic tissue [27].
It may also be assumed that egg white cystatin may
be used to control the activity of cysteine peptidases
that is closely connected with neoplastic processes, as
the protein is structurally similar to autogenous
inhibitors controlling the overexpression of cysteine
peptidases [28].
It has also been observed that when animals with
human neoplasms receive cysteine peptidase inhibitors
isolated from the human placenta both the neoplasm
and VEGF concentration, which affect angiogenesis,
tend to decrease.
Control of VEGF concentration and the use of cys-
teine peptidase inhibitors seem to complement one
another. Taking advantage of the properties of cysteine
peptidase inhibitors originating from the human pla-
centa or chicken egg white, not only is it possible to
control cysteine peptidase activity but also to reduce
the concentration of VEGF and its receptors. Further-
more, a very significant growth of necrosis of the neo-
plastic tumour, which also decreased, was observed
[29,30].
The core purpose of the study was to show that it is
possible to use in vitro cysteine peptidase inhibitors
obtained from egg white as peptides controlling the
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Table 1. Inhibition with egg white cystatins of cysteine peptidase
activity in three ascitic fluid samples obtained from pancreatic
cancer patients.
activity of enzymes responsible for neoplastic process-
es in ascitic fluid of pancreatic cancer patients.
Our in vitro tests suggest that egg white cystatin,
with a molecular weight of 13 kDa, may be added to
ascitic fluid to arrest enzymatic neoplastic processes.
Such a procedure may limit the penetration of the pep-
tide through the peritoneal membrane. This will avoid
the problem observed in the case of intraperitoneal
treatment, when administered cytostatics or TIMP
inhibitors are small synthetic molecules, which pene-
trate into the blood, causing the same reaction as dur-
ing conventional chemotherapy [2].
It is hoped that by using such inhibitors egg white
cystatin will not only arrest the activity of neoplastic
cysteine peptidases in ascitic fluid but also in the very
neoplastic tumour or metastatic locations that show
overexpression of enzymes with high affinity to egg
white cystatin. The arrest or removal from the body of
cysteine peptidases may assist and complement the
intended therapeutic treatments [31].
Conclusions
The idea of inhibition of cysteine peptidases in vivo
holds the promise for future development of totally
new generation of anticancer drugs, which could con-
trol such key processes as transformation, invasion,
metastases, angiogenesis or apoptosis. Application of
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Fig. 2. Inhibition of cysteine pepti-
dase activity in ascitic fluid.
Fig. 1. Cathepsins B and L activi-
ty/1.0 mg protein
new direction of inhibitotherapy utilizing inhibitors of
similar structure to their autogenous analogues
through ascitic fluid may limit negative effects of tox-
icity of the administered drugs while retaining hope for
their effective activity. Obtaining the answer to this
question will be possible only after completion of the
in vivo studies.
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